11 – 20 of 540
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms
(
- Contribution to journal › Scientific review
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
2023) In Leukemia and Lymphoma(
- Contribution to journal › Article
-
Mark
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma : results from a retrospective worldwide registry
(
- Contribution to journal › Article
-
Mark
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
(
- Contribution to journal › Article
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
-
Mark
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCL complete Project
(
- Contribution to journal › Article
-
Mark
Reply to V. Nardone et al
(
- Contribution to journal › Debate/Note/Editorial